Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.36 |
| ▸ | RAF1 | P04049 | 14/20 | 0.35 |
| ▸ | BRAF | P15056 | 14/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27827233 | 0.87 | KDM4D (0.35) | KDM4DRAF1BRAFCYP1A2POLB | |
| SCHEMBL3129450 | 0.84 | KDM4D (0.38) | KDM4DRAF1BRAFCYP1A2POLB | |
| SCHEMBL3131761 | 0.84 | KDM4D (0.38) | KDM4DRAF1BRAFCYP1A2POLB | |
| SCHEMBL567389 | 0.79 | ATM (0.38) | KDM4DRAF1BRAFKDM4E | |
| SCHEMBL27845882 | 0.79 | KDM4D (0.35) | KDM4DRAF1BRAFCYP1A2POLB | |
| SCHEMBL3124166 | 0.79 | KDM4B (0.43) | KDM4DRAF1BRAF | |
| SCHEMBL3120987 | 0.78 | AR (0.43) | KDM4DCYP1A2POLBKDM4ELMNA | |
| SCHEMBL3126279 | 0.75 | PIK3C3 (0.36) | KDM4DRAF1BRAFKDM4EPIK3C3 | |
| SCHEMBL11197523 | 0.74 | KDM4C (0.53) | KDM4DKDM4E | |
| SCHEMBL568566 | 0.74 | MEN1 (0.42) | KDM4DRAF1BRAFKDM4EPIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346868-B1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-8338610-B2 | Pyridinyl compounds useful as intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-25 | — | — | US | disclosed |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-31 | — | — | US | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | KDM4D 1743/4885RAF1 2726/4885BRAF 3808/4885 |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | CCR1, CCRL2, CCR4 | KDM4D 4175/4885RAF1 912/4885BRAF 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.